
    
      This is an open labeled prospective trial with race matched historical controls. The
      treatment group (experimental arm) will be African American de novo solitary renal transplant
      recipients. The control arm will consist of race matched solitary renal transplant recipients
      who received a Cyclosporine (CsA) -based immunosuppressive regimen. The subjects will be
      matched for organ source (living donor vs. cadaveric). The experimental treatment arm will
      have an immunosuppression regimen consisting of Sirolimus, Reduced dose cyclosporine,
      Thymoglobulin, and only 3 doses of steroids.
    
  